{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:37:56Z","timestamp":1762979876563,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.clgc.2011.11.005","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T14:38:28Z","timestamp":1329143908000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community"],"prefix":"10.1016","volume":"10","author":[{"given":"Guru","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deidre","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Tourtellott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Lance","family":"Cowey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Hellerstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2011.11.005_bib1","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.1997.15.7.2564","article-title":"Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"15","author":"Saxman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib2","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib3","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"year":"2010","key":"10.1016\/j.clgc.2011.11.005_bib5"},{"key":"10.1016\/j.clgc.2011.11.005_bib6","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.bjc.6602112","article-title":"A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer","volume":"91","author":"Hussain","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2011.11.005_bib9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1023\/A:1008331111654","article-title":"Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial","volume":"10","author":"von der Maase","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib10","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib11","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II\u2014results of EORTC study 30986","volume":"27","author":"De Santis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib12","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/cncr.24313","article-title":"Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma","volume":"115","author":"Calabro","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2011.11.005_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2011.11.005_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1","article-title":"Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients","volume":"77","author":"Petrioli","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2011.11.005_bib15","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2011.11.005_bib16","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","author":"Galsky","year":"2011","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2011.11.005_bib17","article-title":"Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced\/metastatic urothelial carcinoma (UC)","volume":"29","author":"Balar","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clgc.2011.11.005_bib18","doi-asserted-by":"crossref","first-page":"LBA5030","DOI":"10.1200\/jco.2007.25.18_suppl.lba5030","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine (PCG) and gemcitabine\/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987\/Intergroup Study","volume":"25","author":"Bellmunt","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"25","key":"10.1016\/j.clgc.2011.11.005_bib19","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1200\/JCO.2010.29.1047","article-title":"First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?","volume":"28","author":"Sonpavde","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib20","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1200\/JCO.2007.13.0856","article-title":"Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer","volume":"25","author":"Butts","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2011.11.005_bib21","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/annonc\/mdr023","article-title":"Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity","volume":"22","author":"Bellmunt","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311001054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311001054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:19:43Z","timestamp":1761563983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767311001054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1558767311001054"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2011.11.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Administration of Cisplatin-Based Chemotherapy for Advanced Urothelial Carcinoma in the Community","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2011.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}